In this analysis of prognostic factors for patients with stage III NSCLC treated with concurrent CRT and durvalumab, our pertinent findings include that patients with very high PD-L1 expression (TPS ≥ 90%) have significantly prolonged PFS, and equally important, those with PD-L1 negative disease have outcomes similar to patients with PD-L1 low (TPS 1–49%) tumors. This evidence concerns the gene CD274 and non-small cell lung carcinoma.